hGHRH(1-32)NH2 vs L-692,429
Head-to-head comparison of hGHRH(1-32)NH2 (Human growth hormone-releasing factor (1-32) amide) and L-692,429 (L-692,429) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | hGHRH(1-32)NH2 | L-692,429 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Full Name | Human growth hormone-releasing factor (1-32) amide | L-692,429 |
| Molecular Weight | N/A | N/A |
| Half-Life | 5-15 minutes | unknown / study-dependent |
| Amino Acids | 32 | N/A |
| Typical Dose | 0.1-1 mcg/kg | 0.03-0.1 mg/kg |
| Route | Subcutaneous/IV | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 50 | 30 |
| Research Status | Clinical Research | Pre-clinical |
hGHRH(1-32)NH2 Benefits
- ✓GH pulse induction
- ✓core-sequence testing
- ✓receptor signaling studies
- ✓protease-resistance comparisons
L-692,429 Benefits
- ✓potent GHSR agonism
- ✓oral bioactivity in models
- ✓validates ghrelin pathway
- ✓useful research probe
hGHRH(1-32)NH2 Dosing
0.1-1 mcg/kg SC or IV bolus|acute GH-response testing with timed blood draws|pulsatile dosing in receptor studies
L-692,429 Dosing
0.03-0.1 mg/kg in early studies|single oral or short-course research dosing|serial GH sampling recommended
hGHRH(1-32)NH2 Side Effects
- ⚠headache
- ⚠flushing
- ⚠injection-site irritation
L-692,429 Side Effects
- ⚠increased appetite
- ⚠glucose intolerance
- ⚠transient prolactin changes
Research Overview
hGHRH(1-32)NH2
Human GHRF(1-32)NH2 is used in basic and translational studies to evaluate how the active N-terminal region of GHRH drives pituitary hormone release. It helps define the lower bound of sequence length needed for meaningful biological activity.
L-692,429
L-692,429 was important in early GH secretagogue research because it showed that nonpeptide molecules could trigger robust GH release. It remains a classic tool compound for studying receptor-mediated GH pulsatility and appetite signaling.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.